Borviz 2.5 Mg Injection

Product Description

Borviz 2.5 mg Injection typically contains Bortezomib as the active ingredient. Bortezomib is a proteasome inhibitor used in the treatment of certain cancers, particularly multiple myeloma and mantle cell lymphoma.

Here are the key details about Borviz 2.5 mg Injection:

• Active Ingredient: Bortezomib

• Common Uses:

  • Treatment of multiple myeloma, a cancer of the plasma cells in the bone marrow.
  • Treatment of mantle cell lymphoma, a type of non-Hodgkin lymphoma.

• Mechanism of Action:

  • Bortezomib works by inhibiting the proteasome, an enzyme complex responsible for breaking down proteins within cells. By blocking the proteasome, it causes an accumulation of damaged proteins, leading to cell death, particularly in cancer cells that are rapidly dividing.

• Dosage:

  • The exact dosage and treatment schedule will be determined by the healthcare provider based on the patient's condition, age, and other factors. Typically, Borviz is administered through an intravenous (IV) injection or subcutaneously (under the skin).

• Side Effects:

  • Common side effects may include nausea, fatigue, diarrhea, fever, and low blood counts (such as low red or white blood cells).
  • Serious side effects could include neuropathy (nerve damage), blood clotting problems, or heart-related issues.

• Precautions:

  • Close monitoring is required during treatment for potential side effects, especially related to blood counts and nerve function.
  • It is essential to inform the healthcare provider if the patient has any history of heart problems, liver issues, or infections.